Histamine-releasing factor (HRF), HRF-receptor and methods of modulating inflammation
AssigneeLa Jolla Institute for Allergy and Immunology
InventorsToshiaki Kawakami, Yuko Kawakami
Life of this patent
Estimating the term…
Loading patent…
AssigneeLa Jolla Institute for Allergy and Immunology
InventorsToshiaki Kawakami, Yuko Kawakami
Estimating the term…
Methods of treating a food allergy, allergic reactions, hypersensitivity, inflammatory responses, inflammation are provided. In one method, histamine releasing factor (HRF)/translationally controlled tumor protein (TCTP) is contacted with a compound that inhibits or reduces binding of HRF/TCTP to an immunoglobulin in order to treat the food allergy, allergic reaction, hypersensitivity, inflammatory response, or inflammation. Methods of reducing or decreasing the probability, severity, frequency, duration or preventing a subject from having an acute or chronic food allergy, allergic reaction, hypersensitivity, an inflammatory response or inflammation, are also provided. In one method, histamine releasing factor (HRF)/translationally controlled tumor protein (TCTP) is contacted with a compound that inhibits or reduces binding of HRF/TCTP to an immunoglobulin in order to reduce or decrease the probability, severity, frequency, duration or prevent a subject from having an acute or chronic food allergy, allergic reaction, hypersensitivity, an inflammatory response or inflammation.
A method of treating an allergic reaction, hypersensitivity, an inflammatory response or inflammation in a subject, comprising administering to the subject a peptide inhibitor of histamine releasing factor (HRF)/translationally controlled tumor protein (TCTP) receptor interaction, said peptide inhibitor consisting of amino acids 1-19 or amino acids 79-142 of SEQ ID NO:3 thereby treating the allergic reaction, hypersensitivity, inflammatory response or inflammation.
Dependencies are inferred from the claim text.